PulseMedica

Focus: PulseMedica is a public biotechnology company headquartered in Edmonton, AB, focused on vitreoretinal screening technologies and ophthalmology solutions. The company operates at a specialized stage with a narrow therapeutic focus on diabetic retinopathy and floaters.

Ophthalmology

Profile data last refreshed 57m ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

4+2 this month

Stable — net +2 jobs in 30d

3 added, 1 removed. Backfill posture.

Should You Work at PulseMedica?

AI assessment

PulseMedica represents a high-risk, niche-specialist opportunity best suited to early-career scientists seeking deep ophthalmology expertise; limited scale and opaque financial health make it a poor choice for those prioritizing job security or near-term advancement.

Why Work Here

Niche expertise in ophthalmology/vitreoretinal disease with potential for deep domain knowledge and specialization in an underserved area

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

SVO-ID

Floaters

N/A

Clinical Trials (1)

NCT06097897Imaging of Vitreous Opacities in Human Eyes

N/A

Help build intelligence for PulseMedica

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides equity upside and career visibility compared to private-stage peers

Focused pipeline targeting high-prevalence conditions (diabetic retinopathy affects ~100M globally) with clear clinical needs

Watch Out For

Minimal active hiring (only 2 roles open) and sparse publicly available information suggest a very small organization with limited career trajectory and mentorship diversity
No published clinical trial data, revenue figures, or recent news in available records—raises questions about development progress, commercialization strategy, and organizational transparency
Early-stage pipeline with no programs beyond Phase 2 equivalent indicates long commercialization runway and heightened risk of clinical or regulatory setbacks

Generated by Claude from PulseMedica's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SVO-ID

Floaters

N/A

Clinical Trials (1)

NCT06204848Imaging of Vitreous Opacities in a Canadian Population

N/A

OSNAT 800 IO

Diabetic Retinopathy

N/A

Clinical Trials (1)

NCT05608265Real-time Eye Tracking and Imaging of the Eye in Diabetic Retinopathy Patients

N/A

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Ophthalmology

Open Roles: 4 active jobs

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Ophthalmology

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

PulseMedica

Should You Work at PulseMedica?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (4)

Director of Finance

Project Manager, Medical Device R&D

Regulatory Affairs Intern

Senior Optical Engineer

Hiring Trend